Staar Surgical bares alliance with Asian Eye Institute
LAKE FOREST, Calif.– STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, announced that it has entered a strategic alliance with Asian Eye Institute, an eye care group with nine locations in the Philippines.
“‘Amazing’, ‘Wow’, ‘It’s so clear’, and ‘I am so happy’ are the words I often hear after performing the Visian® EVO ICL procedure and I am confident and proud to partner with STAAR in offering the EVO family of lenses to my patients,” said Dr. Robert Edward Ang, senior consultant and head of cornea and refractive surgery services at Asian Eye Institute.
“Patient reactions to their new EVO lenses always give me a big smile. It’s truly remarkable that EVO can deliver such outstanding results very consistently. Even if a patient has low to moderate refractive error and is qualified for Lasik, PRK or SMILE, I can present the patient an option for outstanding quality vision with the ICL and without removing tissue from the cornea and risking ectasia. Thin corneas, suspicious topographies, and high refractive errors are also no longer a hindrance to giving a patient great vision with the implantable Collamer lens. Not many products can make a doctor feel this way.”
Asian Eye Institute was founded in 2001 and has 18 medical doctors, two specialist optometrists, and more than 30 staff optometrists on staff across its nine locations.
“Dr. Bobby Ang and the Asian Eye Institute are renowned for their high level of patient care and extensive research within the field of ophthalmology,” said Caren Mason, president and CEO of STAAR Surgical.
“Asian countries, such as the Philippines, are among the hardest hit by the explosive growth in myopia and, in particular, progressive high myopia that can lead to more serious eye disease such as glaucoma and retinal detachment. The ICL is an excellent option for these, and many other patients with a wide range of vision correction needs who also seek independence from disposable contact lenses and glasses. “Ang was recognized by
The Ophthalmologist on the 2018 Power List 100, which features top innovators in the field of ophthalmology. He has also conducted important research relating to the ICL, having presented his work at STAAR’s annual Experts Meetings during the European Society of Cataract and Refractive Surgery (ESCRS) Congress. The Asian Eye Institute and Ang have demonstrated their commitment to vision care excellence and delighting patients for almost two decades. We are thrilled to expand our partnership through a new Strategic Alliance Agreement,” she added.
Myopia (nearsightedness) is the need for distance vision correction. EVO, also known as the Implantable Collamer Lens, is an additive lens implant that can help correct myopia. Unlike other procedures, the EVO procedure does not remove corneal tissue but works in harmony with the natural eye. EVO rests behind the iris and is biocompatible. 99.4 percent of patients in a Patient Registry said they would have the ICL procedure again.